85845-02-9 Usage
Description
((3-(Trifluoromethyl)phenyl)sulfonyl)amino)acetic acid is a sulfonamide derivative with the chemical formula C9H9F3NO4S, featuring an amino acid group and a trifluoromethyl group on the phenyl ring. (([3-(TRIFLUOROMETHYL)PHENYL]SULFONYL)AMINO)ACETIC ACID is known for its enhanced acidity due to the strong electron-withdrawing trifluoromethyl group. Its unique structure and functional groups make it a promising candidate for research and development in pharmaceutical, agrochemical industries, and new material development.
Uses
Used in Pharmaceutical Industry:
((3-(Trifluoromethyl)phenyl)sulfonyl)amino)acetic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its acidic and electron-withdrawing properties make it suitable for the development of new therapeutic agents with improved pharmacological properties.
Used in Agrochemical Industry:
In the agrochemical industry, ((3-(Trifluoromethyl)phenyl)sulfonyl)amino)acetic acid is used as a building block for the synthesis of agrochemicals, such as herbicides, insecticides, and fungicides. Its unique structure and functional groups can contribute to the development of more effective and environmentally friendly agrochemicals.
Used in New Material Development:
((3-(Trifluoromethyl)phenyl)sulfonyl)amino)acetic acid is used as a key component in the development of new materials with specific properties. Its unique structure and functional groups can be utilized to create materials with enhanced performance in various applications, such as sensors, catalysts, and advanced materials for energy storage and conversion.
Check Digit Verification of cas no
The CAS Registry Mumber 85845-02-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,8,4 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 85845-02:
(7*8)+(6*5)+(5*8)+(4*4)+(3*5)+(2*0)+(1*2)=159
159 % 10 = 9
So 85845-02-9 is a valid CAS Registry Number.
InChI:InChI=1/C9H8F3NO4S/c10-9(11,12)6-2-1-3-7(4-6)18(16,17)13-5-8(14)15/h1-4,13H,5H2,(H,14,15)
85845-02-9Relevant articles and documents
Protease inhibitors - Part 5. Alkyl/arylsulfonyl- and arylsulfonylureido-/arylureido- glycine hydroxamate inhibitors of Clostridium histolyticum collagenase
Scozzafava, Andrea,Supuran, Claudiu T.
, p. 299 - 307 (2007/10/03)
Reaction of alkyl/arylsulfonyl halides with glycine afforded a series of derivatives which were first N-benzylated by treatment with benzyl chloride, and then converted to the corresponding hydroxamic acids with hydroxylamine in the presence of carbodiimide derivatives. Other derivatives were obtained by reaction of N-benzyl-glycine with aryl isocyanates, arylsulfonyl isocyanates or benzoyl isothiocyanate, followed by conversion of their COOH group into the CONHOH moiety, as mentioned above. The 90 new compounds reported here were assayed as inhibitors of the Clostridium histolyticum collagenase (EC 3.4.24.3), a zinc enzyme which degrades triple helical regions of native collagen. The prepared hydroxamate derivatives were generally 100-500 times more active than the corresponding carboxylates. In the series of synthesized hydroxamates, substitution patterns leading to the best inhibitors were those involving perfluoroalkylsulfonyl- and substituted- arylsulfonyl moieties, such as pentafluorophenylsulfonyl, 3- and 4- carboxyphenylsulfonyl-, 3-trifluoromethyl-phenylsulfonyl or 1- and 2-naphthyl among others. Thus, it seems that similarly to the matrix metalloproteinase (MMP) hydroxamate inhibitors, Clostridium histolyticum collagenase inhibitors should incorporate hydrophobic moieties at the P1, and P2, sites, whereas the α-carbon substituent may be a small and compact moiety (such as H. for the Gly derivatives reported here). Such compounds might lead to the design of collagenase inhibitor-based drugs useful as anti-cancer, anti-arthritis or anti-bacterial agents for the treatment of corneal keratitis. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
